Physician profile
Sarit Vaserman
NPI 1154725604
$800.04
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $714 · 2022: $85.60.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $185.59 | 2021-2022 | |
| Genzyme Corporation | $121.85 | 2021 | |
| Daiichi Sankyo INC. | $115.39 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $97.86 | 2021 | |
| Celgene Corporation | $90.42 | 2021 | |
| Eisai INC. | $70.44 | 2021 | |
| Sanofi-Aventis U.S. LLC | $64.99 | 2021 | |
| Puma Biotechnology, INC. | $53.50 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarit Vaserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.